A multi-country implementation research initiative to jump-start scale-up of outpatient management of possible serious bacterial infections (PSBI) when a referral is not feasible: Summary findings and implications for programs.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
01
2022
accepted:
23
05
2022
entrez:
13
6
2022
pubmed:
14
6
2022
medline:
16
6
2022
Statut:
epublish
Résumé
Research on simplified antibiotic regimens for outpatient treatment of 'Possible Serious Bacterial Infection' (PSBI) and the subsequent World Health Organization (WHO) guidelines provide an opportunity to increase treatment coverage. This multi-country implementation research initiative aimed to learn how to implement the WHO guideline in diverse contexts. These experiences have been individually published; this overview paper provides a summary of results and lessons learned across sites. A common mixed qualitative and quantitative methods protocol for implementation research was used in eleven sites in the Democratic Republic of Congo (Equateur province), Ethiopia (Tigray and Oromia regions), India (Haryana, Himachal Pradesh, Maharashtra, and Uttar Pradesh states), Malawi (Central Region), Nigeria (Kaduna and Oyo states), and Pakistan (Sindh province). Key steps in implementation research were: i) policy dialogue with the national government and key stakeholders, ii) the establishment of a 'Technical Support Unit' with the research team and district level managers, and iii) development of an implementation strategy and its refinement using an iterative process of implementation, programme learning and evaluation. All sites successfully developed and evaluated an implementation strategy to increase coverage of PSBI treatment. During the study period, a total of 6677 young infants from the study catchment area were identified and treated at health facilities in the study area as inpatients or outpatients among 88179 live births identified. The estimated coverage of PSBI treatment was 75.7% (95% CI 74.8% to 78.6%), assuming a 10% incidence of PSBI among all live births. The treatment coverage was variable, ranging from 53.3% in Lucknow, India to 97.3% in Ibadan, Nigeria. The coverage of inpatient treatment ranged from 1.9% in Zaria, Nigeria, to 33.9% in Tigray, Ethiopia. The outpatient treatment coverage ranged from 30.6% in Pune, India, to 93.6% in Zaria, Nigeria. Overall, the case fatality rate (CFR) was 14.6% (95% CI 11.5% to 18.2%) for 0-59-day old infants with critical illness, 1.9% (95% CI 1.5% to 2.4%) for 0-59-day old infants with clinical severe infection and 0.1% for fast breathing in 7-59 days old. Among infants treated as outpatients, CFR was 13.7% (95% CI 8.7% to 20.2%) for 0-59-day old infants with critical illness, 0.9% (95% CI 0.6% to 1.2%) for 0-59-day old infants with clinical severe infection, and 0.1% for infants 7-59 days old with fast breathing. Important lessons on how to conduct each step of implementation research, and the challenges and facilitators for implementation of PSBI management guideline in routine health systems are summarised and discussed. These lessons will be used to introduce and scale-up implementation in relevant Low- and middle-income countries.
Identifiants
pubmed: 35696401
doi: 10.1371/journal.pone.0269524
pii: PONE-D-22-01553
pmc: PMC9191694
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0269524Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
The authors declare that no competing interests exist. Some of the authors are currently and/or were previously employed by not-for-profit organizations including: Save the Children, World Health Organization, BMGF, USAID, UNICEF, and ActionAid. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
PLoS One. 2020 Apr 22;15(4):e0229988
pubmed: 32320993
Lancet. 1999 Dec 4;354(9194):1955-61
pubmed: 10622298
PLoS One. 2021 Jul 7;16(7):e0252700
pubmed: 34234352
Front Public Health. 2018 Mar 22;6:71
pubmed: 29623270
Lancet. 2004 Jun 12;363(9425):1948-53
pubmed: 15194254
Pediatr Infect Dis J. 2012 Jul;31(7):667-72
pubmed: 22481421
PLoS One. 2020 Oct 14;15(10):e0240688
pubmed: 33052981
PLoS One. 2020 Mar 10;15(3):e0228718
pubmed: 32155155
Lancet Glob Health. 2015 May;3(5):e279-87
pubmed: 25841891
Lancet Infect Dis. 2014 Aug;14(8):731-741
pubmed: 24974250
Sisli Etfal Hastan Tip Bul. 2020 Jun 12;54(2):142-158
pubmed: 32617051
BMJ Glob Health. 2019 Nov 19;4(6):e001643
pubmed: 31803507
PLoS One. 2021 Aug 9;16(8):e0255210
pubmed: 34370744
PLoS One. 2021 Mar 15;16(3):e0247977
pubmed: 33720960
PLoS One. 2020 Aug 24;15(8):e0236355
pubmed: 32833993
PLoS One. 2020 Apr 14;15(4):e0229248
pubmed: 32287262
PLoS One. 2020 Dec 22;15(12):e0243724
pubmed: 33351810
BMC Pediatr. 2020 Aug 29;20(1):409
pubmed: 32861246
PLoS One. 2021 Mar 30;16(3):e0248720
pubmed: 33784321
Lancet. 2015 May 2;385(9979):1767-1776
pubmed: 25842221
Lancet. 2008 Jun 7;371(9628):1936-44
pubmed: 18539225
PLoS One. 2020 Jun 4;15(6):e0234212
pubmed: 32497092
PLoS One. 2021 Feb 5;16(2):e0244192
pubmed: 33544712
Lancet Glob Health. 2017 Feb;5(2):e177-e185
pubmed: 27988146
J Public Health (Oxf). 2022 Feb 09;:
pubmed: 35138390
J Perinatol. 2011 Sep;31(9):586-92
pubmed: 21273989
PLoS One. 2020 Apr 14;15(4):e0231490
pubmed: 32287286
BMJ. 2012 Mar 20;344:e1717
pubmed: 22434089
BMC Public Health. 2015 Sep 30;15:989
pubmed: 26419934
PLoS One. 2020 May 11;15(5):e0232675
pubmed: 32392209
J Glob Health. 2016 Jun;6(1):010408
pubmed: 27231544
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Malawi Med J. 2014 Dec;26(4):126-32
pubmed: 26167263
Lancet. 2015 May 2;385(9979):1758-1766
pubmed: 25842223